Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX) has rescinded a US$2.5 million investor relations agreement with IR Agency LLC and recovered the full fee. The company is postponing its marketing push while it exits the TSX Venture Exchange.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. has re-engaged IR Agency LLC for investor relations and marketing services, following completion of its voluntary delisting from the TSX Venture Exchange.

XORTX restores IR Agency LLC consulting agreement on previously disclosed terms

The new consulting agreement carries substantially the same terms the company disclosed in news releases dated May 19, 2026 and August 28, 2026. The source gives no fee, share-based compensation or contract-length figures for the renewed engagement.

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX) plans to submit an Investigational New Drug application to the U.S. FDA in the fourth quarter of 2026 for its XRx-026 gout program, and estimates the program addresses a US$700M annual market opportunity.

Milan – October 09, 2026 -- WuXi Biologics is pitching a European manufacturing footprint of 54,000 L of drug-substance capacity in Dundalk, Ireland, plus a 12,000 L site in Wuppertal, Germany, to biopharma clients at CPHI Milan 2026, as Europe's biologics market is projected to grow from an estimated US$123.75 billion in 2025 to about US$269.65 billion by 2035.

The market is forecast to expand at a CAGR of 8.1% from 2026 to 2035. CPHI Milan 2026 brings together more than 62,000 pharmaceutical professionals and 2,900 exhibitors.

Piscataway, N.J. – October 08, 2026 -- GenScript Biotech Corporation and NVIDIA have launched a global startup competition pairing wet lab validation with accelerated computing to push AI-driven drug discovery toward commercial proof points.

Hong Kong – October 08, 2026 -- Sisram Medical Ltd (1696.HK) has announced a share repurchase plan to buy back up to 1% of its total issued shares on the open market, citing confidence in its long-term growth trajectory.

New Haven, Conn. – October 08, 2026 -- Biohaven Ltd. (NYSE: BHVN) has signed a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. (TYO: 4528), granting Ono exclusive rights to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio across Japan, South Korea, Taiwan, and ASEAN member states.

Suzhou – October 7, 2026 -- Suzhou Ribo Life Science (06938.HK) and its Swedish subsidiary Ribocure Pharmaceuticals AB have submitted a Phase I Clinical Trial Application in the European Union for RBD3133, a small interfering RNA (siRNA) therapeutic targeting the INHBE gene for overweight and obesity.

Shanghai – October 07, 2026 -- WuXi AppTec has secured its third consecutive Gold medal from EcoVadis, placing the pharmaceutical CRDMO among the top 5% of companies worldwide for sustainability performance.

Delray Beach, Fla. – – October 07, 2026 -- The global Active Pharmaceutical Ingredients (API) market will grow from USD 149.02 billion in 2026 to USD 199.42 billion by 2031, a 6.0% compound annual growth rate, according to new data from MarketsandMarkets.